


PHARMACEUTICAL 2019

DiaMedica Therapeutics Inc. Rank 110 of 371









PHARMACEUTICAL 2019



DiaMedica Therapeutics Inc. Rank 110 of 371

The relative strengths and weaknesses of DiaMedica Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DiaMedica Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 236% points. The greatest weakness of DiaMedica Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is -46%, being 285% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	17,972
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,296
Liabilities, Non-Current	18
Other Assets	271
Other Compr. Net Income	0
Other Expenses	80
Other Liabilities	0
Other Net Income	1,107
Property and Equipment	96
Research and Development	4,522
Revenues	500
Selling, General and Administrative Expense	2,739

Output Variable	Value in 1000 USD
Assets	18,339
Liabilities	1,314
Expenses	7,341
Stockholders Equity	17,025
Net Income	-5,734
Comprehensive Net Income	-5,734
Economic Capital Ratio	-46%

